Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

Kelly C. Gast, Paul V. Viscuse, Somaira Nowsheen, Tufia C Haddad, Robert Mutter, Andrea E Wahner Hendrickson, Fergus J Couch, Kathryn J Ruddy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of review: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. Recent findings: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Summary: Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.

Original languageEnglish (US)
Article number18
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume20
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Mutation
Radiotherapy
Thorax
Guidelines
Drug Therapy
Therapeutics
Population
Neoplasms

Keywords

  • BRCA mutation
  • Cardio-oncology
  • Chemotherapy cardiotoxicity
  • Radiation cardiotoxicity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. / Gast, Kelly C.; Viscuse, Paul V.; Nowsheen, Somaira; Haddad, Tufia C; Mutter, Robert; Wahner Hendrickson, Andrea E; Couch, Fergus J; Ruddy, Kathryn J.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 20, No. 2, 18, 01.02.2018.

Research output: Contribution to journalReview article

@article{496acf02c5ea476eb20d656f0c3f5dbf,
title = "Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers",
abstract = "Purpose of review: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. Recent findings: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Summary: Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.",
keywords = "BRCA mutation, Cardio-oncology, Chemotherapy cardiotoxicity, Radiation cardiotoxicity",
author = "Gast, {Kelly C.} and Viscuse, {Paul V.} and Somaira Nowsheen and Haddad, {Tufia C} and Robert Mutter and {Wahner Hendrickson}, {Andrea E} and Couch, {Fergus J} and Ruddy, {Kathryn J}",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s11936-018-0609-z",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

AU - Gast, Kelly C.

AU - Viscuse, Paul V.

AU - Nowsheen, Somaira

AU - Haddad, Tufia C

AU - Mutter, Robert

AU - Wahner Hendrickson, Andrea E

AU - Couch, Fergus J

AU - Ruddy, Kathryn J

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose of review: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. Recent findings: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Summary: Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.

AB - Purpose of review: BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. Recent findings: BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Summary: Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.

KW - BRCA mutation

KW - Cardio-oncology

KW - Chemotherapy cardiotoxicity

KW - Radiation cardiotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85042792830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042792830&partnerID=8YFLogxK

U2 - 10.1007/s11936-018-0609-z

DO - 10.1007/s11936-018-0609-z

M3 - Review article

VL - 20

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 2

M1 - 18

ER -